Harvard Pilgrim Health Care | TUFTS Health Plan

Pharmacy Medical Necessity Guidelines: **Zymfentra (infliximab-dyyb) Subcutaneous**

Effective: July 1, 2026

Guideline Type	☒ Prior Authorization ☒ Non-Formulary ☐ Step-Therapy ☐ Administrative

Applies to:

Commercial Products

☒ Harvard Pilgrim Health Care Commercial products; Fax: 617-673-0988

☒ Tufts Health Plan Commercial products; Fax: 617-673-0988

Public Plans Products

☒ Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product); Fax: 617-673-0988

Note: While you may not be the provider responsible for obtaining prior authorization, as a condition of payment you will need to ensure that prior authorization has been obtained.

Overview

Food and Drug Administration – Approved Indications

Zymfentra (infliximab-dyyb) is a tumor necrosis factor indicated for:

Disease State	
Crohn's disease	X
Ulcerative colitis	X

Clinical Guideline Coverage Criteria

The plan may authorize coverage of Zymfentra Subcutaneous for Members when **ALL** of the following criteria are met:

Crohn's Disease

Initial Authorization Criteria

1. Documented diagnosis of moderately to severely active Crohn's disease

AND

2. Documentation of previous treatment with an infliximab product administered intravenously

AND

3. Patient is at least 18 years of age or older

AND

4. Prescribed by a gastroenterologist

AND

5. Documentation of history of failure to **one (1)** of the following, unless contraindicated or clinically significant adverse effects are experienced *(Note: document drug, date, and duration of trial):*
    a. Corticosteroid
    b. 5-aminosalyclate
    c. 6-mercaptopurine
    d. Methotrexate

AND

6. Documentation of history of failure to at least **two (2)** of the following medications from each of the following therapeutic categories (only one medication is required if only one is available for a listed therapeutic category), unless contraindicated (*Note: document drugs, dates, and duration of trials*):
    a. Interleukin Antagonists: Omvoh, Skyrizi, Tremfya, or Yesintek or Starjemza
    b. Janus Kinase Inhibitors: Rinvoq
    c. Tumor Necrosis Factors: Cimzia, Simlandi

AND

7. Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug

Reauthorization Criteria

1. Documentation the patient has been established on the requested medication for at least 12 months

AND

2. Documented diagnosis of moderately to severely active Crohn's disease

AND

3. Patient is at least 18 years of age or older

AND

4. Prescribed by a gastroenterologist

AND

5. Documentation of clinically significant improvement or stabilization in clinical signs and symptoms of disease as determined by the prescriber

AND

6. Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug

Ulcerative Colitis

Initial Authorization Criteria

1. Documented diagnosis of moderately to severely active ulcerative colitis

AND

2. Documentation of previous treatment with an infliximab product administered intravenously

AND

3. Patient is at least 18 years of age or older

AND

4. Prescribed by a gastroenterologist

AND

5. Documentation of history of failure to **one (1)** of the following, unless contraindicated or clinically significant adverse effects are experienced *(Note: document drug, date, and duration of trial):*
    a. Corticosteroid
    b. 5-aminosalycylate
    c. 6-mercaptopurine
    d. Methotrexate

AND

6. Documentation of history of failure to at least **two (2)** of the following medications from each of the following therapeutic categories (only one medication is required if only one is available for a listed therapeutic category), unless contraindicated (*Note: document drugs, dates, and duration of trials*):
    a. Interleukin Antagonists: Omvoh, Skyrizi, Tremfya, or Yesintek or Starjemza
    b. Janus Kinase Inhibitors: Rinvoq, Xeljanz
    c. Sphingosine 1-phosphate receptor modulator: Zeposia
    d. Tumor Necrosis Factors: Simlandi, Simponi

AND

7. Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug

Reauthorization Criteria

1. Documentation the patient has been established on the requested medication for at least 12 months

AND

2. Documented diagnosis of moderately to severely active ulcerative colitis

AND

3. Patient is at least 18 years of age or older

AND

4. Prescribed by a gastroenterologist

AND

5. Documentation of clinically significant improvement or stabilization in clinical signs and symptoms of disease as determined by the prescriber

AND

6. Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug

Limitations

1. Members who have already initiated the requested medication using samples, free goods, similar offerings, or self-paying for the medication directly do not qualify for an established clinical response and should be reviewed against initial approval criteria.
2. Authorizations will be provided in 12-month intervals.
3. A patient who has received less than 12 months of therapy or who is restarting therapy with the requested drug is reviewed under Initial Authorization Criteria.
4. Members new to the plan stable on the requested medication should be reviewed against Initial Authorization Criteria.

Codes

None

References

1. Zymfentra (infliximab-dyyb) [prescribing information]. Jersey City, NJ, Celltrion USA, Inc; 2024 February
2. Singh S, Loftus EV, Jr, Limketkai BN, et al. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2024 Dec;167(7):1307-1343.
3. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol. 2018;113:481-517.

Approval And Revision History

June 10, 2025: Reviewed by the Pharmacy & Therapeutics Committee (eff 9/15/25).

- October 14, 2025: Approvals limited to 12 months with annual reauthorization coverage criteria added. Provider requirements no longer allow with in consultation with the specialist. Added coverage criteria to prevent duplicative targeted immunomodulator therapy. For Initial Authorization Criteria, updated diagnosis requirements, added “Documentation of previous treatment with an infliximab product administered intravenously”, and added nonbiologic prerequisites. (eff 1/1/26).
- December 9, 2025: Replaced Humira with Simlandi as Simlandi is the preferred adalimumab product (eff 3/1/26).
- June 9, 2026: Added Starjemza as a prerequisite for Crohn’s disease and ulcerative colitis to support the updated ustekinumab strategy – Yesintek and Starjemza are the preferred ustekinumab products. Administrative update to the limitation statement to include members initiated on the requested medication by self-paying for the medication directly do not qualify for established clinical response and should be reviewed against initial approval criteria. Administrative update to remove CareLink from Medical Necessity Guideline template. (eff 7/1/26).

Background, Product and Disclaimer Information

Pharmacy Medical Necessity Guidelines have been developed for determining coverage for plan benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. The plan makes coverage decisions on a case-by-case basis considering the individual member's health care needs. Pharmacy Medical Necessity Guidelines are developed for selected therapeutic classes or drugs found to be safe, but proven to be effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in the service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. The plan revises and updates Pharmacy Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

For self-insured plans, coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a Pharmacy Medical Necessity Guideline and a self-insured Member’s benefit document, the provisions of the benefit document will govern.

Treating providers are solely responsible for the medical advice and treatment of members. The use of this policy is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization and utilization management guidelines when applicable, and adherence to plan policies and procedures and claims editing logic.